Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.
Park C, Suh KJ, Kim SH, Lee KH, Im SA, Kim MH, Sohn J, Jeong JH, Jung KH, Lee KE, Park YH, Kim HJ, Cho EK, Choi IS, Noh SJ, Shin I, Cho DY, Kim JH.
Park C, et al. Among authors: noh sj.
Cancer Immunol Immunother. 2024 Aug 6;73(10):197. doi: 10.1007/s00262-024-03782-7.
Cancer Immunol Immunother. 2024.
PMID: 39105849
Free PMC article.
Clinical Trial.